Provectus commences PH-10 Phase 2c trial for psoriasis

[News]

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.

More... (http://www.news-medical.net/news/20101214/Provectus-commences-PH-10-Phase-2c-trial-for-psoriasis.aspx)